124 related articles for article (PubMed ID: 8572738)
1. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis.
Beyeler C; Armstrong M; Bird HA; Idle JR; Daly AK
Ann Rheum Dis; 1996 Jan; 55(1):66-8. PubMed ID: 8572738
[TBL] [Abstract][Full Text] [Related]
2. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.
Beyeler C; Daly AK; Armstrong M; Astbury C; Bird HA; Idle JR
J Rheumatol; 1994 Jun; 21(6):1034-9. PubMed ID: 7932410
[TBL] [Abstract][Full Text] [Related]
3. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis.
Brown MA; Edwards S; Hoyle E; Campbell S; Laval S; Daly AK; Pile KD; Calin A; Ebringer A; Weeks DE; Wordsworth BP
Hum Mol Genet; 2000 Jul; 9(11):1563-6. PubMed ID: 10861282
[TBL] [Abstract][Full Text] [Related]
5. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
[TBL] [Abstract][Full Text] [Related]
6. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
7. Mutant debrisoquine hydroxylation genes in Parkinson's disease.
Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR
Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 allelic frequencies in young-onset Parkinson's disease.
Sandy MS; Armstrong M; Tanner CM; Daly AK; Di Monte DA; Langston JW; Idle JR
Neurology; 1996 Jul; 47(1):225-30. PubMed ID: 8710083
[TBL] [Abstract][Full Text] [Related]
9. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis.
Jorge LF; Arias TD; Griese U; Nebert DW; Eichelbaum M
Pharmacogenetics; 1993 Oct; 3(5):231-8. PubMed ID: 7904509
[TBL] [Abstract][Full Text] [Related]
10. Association between the oxidative polymorphism and early onset of Parkinson's disease.
Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F
Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 genes and risk of liver cancer.
Agúndez JA; Ledesma MC; Benítez J; Ladero JM; Rodríguez-Lescure A; Díaz-Rubio E; Díaz-Rubio M
Lancet; 1995 Apr; 345(8953):830-1. PubMed ID: 7898230
[TBL] [Abstract][Full Text] [Related]
12. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
13. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.
Dawson E; Powell JF; Nöthen MM; Crocq MA; Lanczik M; Körner J; Rietschel M; van Os J; Wright P; Gill M
Psychiatr Genet; 1994; 4(4):215-8. PubMed ID: 7712118
[TBL] [Abstract][Full Text] [Related]
14. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
[TBL] [Abstract][Full Text] [Related]
15. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis.
Siddons MA; Pickering-Brown SM; Mann DM; Owen F; Cooper PN
Neurosci Lett; 1996 Apr; 208(1):65-8. PubMed ID: 8731176
[TBL] [Abstract][Full Text] [Related]
16. GSTM1 and CYP2D6 genotype frequencies in patients with pituitary tumours: effects on P53, ras and gsp.
Perrett CW; Clayton RN; Pistorello M; Boscaro M; Scanarini M; Bates AS; Buckley N; Jones P; Fryer AA; Gilford J
Carcinogenesis; 1995 Jul; 16(7):1643-5. PubMed ID: 7614700
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population.
Masimirembwa CM; Johansson I; Hasler JA; Ingelman-Sundberg M
Pharmacogenetics; 1993 Dec; 3(6):275-80. PubMed ID: 7908586
[TBL] [Abstract][Full Text] [Related]
19. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
20. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease.
Saitoh T; Xia Y; Chen X; Masliah E; Galasko D; Shults C; Thal LJ; Hansen LA; Katzman R
Ann Neurol; 1995 Jan; 37(1):110-2. PubMed ID: 7818242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
